The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on March 28, 2023. This approval was based on new efficacy data.
What this means
The approval of a supplemental application for efficacy indicates that Keytruda (pembrolizumab) has demonstrated new clinical benefit. Without specific details on the indication or patient population from the provided data, the precise clinical implications for patient care cannot be fully detailed. This type of approval typically expands the drug's approved uses or refines its application based on new evidence.
Source
The information regarding this supplemental approval for Keytruda (pembrolizumab) was obtained from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 125514 S-132, was granted on March 28, 2023, and is publicly accessible on accessdata.fda.gov.